This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Bevespi Improves Lung Function in Phase III Study
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.
Allergan Authorizes New $2B Share Buyback Plan, Stock Up
by Zacks Equity Research
Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.
Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC
by Zacks Equity Research
The FDA slaps a refusal-to-file letter on Allergan's (AGN) Vraylar for its supplemental New Drug Application. The company tries to expand the drug???s label for its use as a maintenance treatment.
Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.
Juno Tenders $250M Follow-on Public Offering of Common Stock
by Zacks Equity Research
Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
by Zacks Equity Research
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.
Implied Volatility Surging for AstraZeneca (AZN) Stock Options
by Zacks Equity Research
AstraZeneca (AZN) needs Investors to pay close attention to the stock based on moves in the options market lately.
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
by Zacks Equity Research
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
Oncology Space in Focus this Week on ESMO Presentations
by Zacks Equity Research
There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.
AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs
by Zacks Equity Research
AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.
Bristol-Myers Reports Positive Results from Melanoma Study
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.
AstraZeneca's Asthma Candidate Shows Promising Results
by Zacks Equity Research
AstraZeneca's asthma candidate, benralizumab, showed promising results in patients who experience more frequent exacerbations despite being on standard-of-care medicines.
AstraZeneca's Lung Cancer Study Data Promising, Shares Spike
by Zacks Equity Research
AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients.
Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis
by Swarup Gupta
North Korea-related tensions weighed on stocks across the world last week.
Company News For Sep 8, 2017
by Zacks Equity Research
Companies in the news are: RH,AZN,GOOGL,CONN
Celgene (CELG) Fusion Program Studies Put on Hold by FDA
by Zacks Equity Research
Celgene Corporation (CELG) announced that the FDA put a hold on several trials in the FUSION program evaluating Imfinzi, an anti-PD-L1 antibody, in combination with immunomodulatory and chemotherapy agents in blood cancers.
AstraZeneca (AZN) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
AstraZeneca (AZN) shares rose more than 5% in the last trading session, amid huge volumes.
Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018
by Arpita Dutt
Key highlights this week include Eli Lilly and Company's (LLY) decision to cut the work force and streamline operations and Merck's efforts to strengthen its immune-oncology franchise.
Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA put a partial clinical hold on three clinical trials, investigating Opdivo-based combinations in patients with relapsed or refractory multiple myeloma.
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.
Merck (MRK) Opts for Buying German Immuno-Oncology Biotech
by Zacks Equity Research
Merck (MRK) to acquire Germany-based Rigontec, a leader in retinoic acid-inducible gene I (RIG-I), a novel immuno-oncology treatment approach targeting therapeutics.
AstraZeneca's COPD Candidate Duaklir Reports Positive Data
by Zacks Equity Research
AstraZeneca Plc (AZN) announced encouraging results from the phase III AMPLIFY study for Duaklir being developed for the treatment of chronic obstructive pulmonary disease (COPD).
4 Drug Stocks Worth a Look on Promising Cancer Pipeline
by Zacks Equity Research
Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?
by Zacks Equity Research
Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services and woes do not end.
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
by Zacks Equity Research
Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.